The Cooper Companies, Inc. (COO)
Healthcare · NMS
Price as at 11 Aug 2026, 18:36 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
The Cooper Companies, Inc. trades at USD76.99, which is 45% above the USD42.27 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 46 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 60.0 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
COO dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2023 | USD0.015 | 2 |
| 2022 | USD0.015 | 2 |
| 2021 | USD0.015 | 2 |
| 2020 | USD0.015 | 2 |
| 2019 | USD0.015 | 2 |
| 2018 | USD0.015 | 2 |
| 2017 | USD0.015 | 2 |
| 2016 | USD0.015 | 2 |
| 2015 | USD0.015 | 2 |
| 2014 | USD0.015 | 2 |
| 2013 | USD0.015 | 2 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
COO earnings and analyst estimates
Recommendation mix, 15 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About The Cooper Companies, Inc.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
COO passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
17 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Al Gore, GENERATION INVESTMENT MANAGEMENT LLP$356.30M · 3.5% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$287.15M · 0.1% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$285.69M · 0.1% of book
- Longview Partners, Longview Partners (Guernsey) LTD$282.54M · 4.6% of book
- Ken Griffin, CITADEL ADVISORS LLC$277.69M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is The Cooper Companies, Inc. (COO) undervalued?
Against our fair value estimate of USD42.27, COO at USD76.99 is 45% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own COO?
17 of the institutions we track reported a position in COO in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is COO's P/E ratio?
COO trades at 60.0 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Where does SteadyShares get its COO data?
Fundamentals for COO come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 11 Aug 2026, 18:36 UTC and is delayed. Our data quality score for this company is 92/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for COO, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.